In the US, Janssen booked sales of $549 million in the last quarter, down almost 19% compared with the same period last year, while outside the US Xarelto generated sales of just over $1bn for Bayer.

Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a ...

According to company’s press statement, the approval has been granted to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. This ...